HF
MDGL icon

HRT Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

HRT Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$261K – 4893
2026
Q1 		$261K Buy
+500
New +$239K ﹤0.01% 2992

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial's MDGL Position: Q2 2026 in Review

HRT Financial opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 84,634 shares worth $45.4M. The stake represents 0.08% of the portfolio and ranks #219 among its holdings. This is a return to the name: HRT Financial previously reported a position in MDGL as recently as Q4 2025.

HRT Financial first reported a position in MDGL in Q3 2019 and has held it in 11 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • HRT Financial held 84,634 shares of Madrigal Pharmaceuticals worth $45.4M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new HRT Financial position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.08% of HRT Financial's portfolio in Q2 2026, its #219 holding.
  • HRT Financial first reported a position in Madrigal Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.